Strong Week For Swine Flu Small-Caps (DVAX, NVS, AZN, GSK, HEB, VICL, APT, SVA, PURE)
Dynavax Technologies (DVAX) shot higher on Thursday after an upgrade to Outperform from Neutral at Wedbush. The analyst more than doubled the firm’s price target to $6, citing optimism for leading product candidate Heplisav, a hepatitis B vaccine currently in Phase 3 testing. Meanwhile, according to the company website, other product candidates are being developed in affiliation with pharmaceutical giants Novartis AG (NVS), AstraZeneca (AZN), and GlaxoSmithKline (GSK).
Dynavax earned its place in the Swine Flu and Bird Flu Stocks Index with the development of a universal flu vaccine, and while H1N1 hype powered the stock and its peers higher during 2009, most small-cap players have fallen sharply to levels supported by other products or businesses.
Over the past five sessions, Dynavax and four other small-cap swine flu players have gained more than 10% as biotech stocks have been heating up. Volatile micro-cap Hemispherx Biopharma (HEB), DNA-vaccine firm Vical (VICL), respirator mask play Alpha Pro Tech (APT), and Chinese biotech Sinovac Biotech (SVA) are all among top performers for the period, but each had fallen by at least a third from its 52-week high.
As of this writing, Pure Bioscience (PURE) is the only small-cap swine flu player to hang within -20% of its annual high-water mark after rocketing higher last month when the EPA cleared its silver-based disinfectant for use in what MarketWatch described as a variety of food-handling settings.
As a whole, the Swine Flu and Bird Flu Stocks Index has lagged the S&P 500 by -3% over the last month, and a look at its performance chart shows the dramatic spike and subsequent pullback in relation to the rise and fall of H1N1 hysteria.
|Home | Find | Research | Track | Register | My Account | Logout||Web site design by LightMix|
|© 2010 Indie research Corp. All rights reserved.|